298 related articles for article (PubMed ID: 21851507)
1. Risk of inhibitor development in mild haemophilia A increases with age.
Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
[TBL] [Abstract][Full Text] [Related]
2. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
[TBL] [Abstract][Full Text] [Related]
3. Treatment related factors and inhibitor development in children with severe haemophilia A.
Maclean PS; Richards M; Williams M; Collins P; Liesner R; Keeling DM; Yee T; Will AM; Young D; Chalmers EA;
Haemophilia; 2011 Mar; 17(2):282-7. PubMed ID: 21070501
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of inhibitors in mild/moderate haemophilia A.
Peerlinck K; Jacquemin M
Haemophilia; 2006 Dec; 12 Suppl 6():43-7. PubMed ID: 17123393
[TBL] [Abstract][Full Text] [Related]
5. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
Chalmers EA; Brown SA; Keeling D; Liesner R; Richards M; Stirling D; Thomas A; Vidler V; Williams MD; Young D;
Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
[TBL] [Abstract][Full Text] [Related]
6. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
[TBL] [Abstract][Full Text] [Related]
8. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
[TBL] [Abstract][Full Text] [Related]
9. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.
Kurnik K; Bidlingmaier C; Engl W; Chehadeh H; Reipert B; Auerswald G
Haemophilia; 2010 Mar; 16(2):256-62. PubMed ID: 19878331
[TBL] [Abstract][Full Text] [Related]
10. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
15. The natural history of mild haemophilia: a 30-year single centre experience.
Tagliaferri A; Di Perna C; Riccardi F; Pattacini C; Rivolta GF; Franchini M
Haemophilia; 2012 Mar; 18(2):166-74. PubMed ID: 21771207
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
Hay CR; Ludlam CA; Colvin BT; Hill FG; Preston FE; Wasseem N; Bagnall R; Peake IR; Berntorp E; Mauser Bunschoten EP; Fijnvandraat K; Kasper CK; White G; Santagostino E
Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
[TBL] [Abstract][Full Text] [Related]
17. Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population.
Boekhorst J; Verbruggen B; Lavergne JM; Costa JM; Schoormans SC; Brons PP; van Kraaij MG; Nováková IR; van Heerde WL
Br J Haematol; 2005 Oct; 131(1):109-17. PubMed ID: 16173970
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitor development after changing FVIII/IX products in patients with haemophilia].
Kocher S; Asmelash G; Makki V; Müller S; Krekeler S; Alesci S; Miesbach W
Hamostaseologie; 2012; 32 Suppl 1():S39-42. PubMed ID: 22961330
[TBL] [Abstract][Full Text] [Related]
19. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
[TBL] [Abstract][Full Text] [Related]
20. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.
Miller CH; Benson J; Ellingsen D; Driggers J; Payne A; Kelly FM; Soucie JM; Craig Hooper W;
Haemophilia; 2012 May; 18(3):375-82. PubMed ID: 22103590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]